Serum infliximab concentrations in pediatric inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 1, 2013, Pages 35-41

  Hämäläinen, Anssi ^a   Sipponen, Taina ^b   Kolho, Kaija Leena ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Crohn's disease; Fecal markers; Therapy; TNF antagonist; Trough levels; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; AGE FACTORS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE;

EID: 84871396379     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.741619     Document Type: Article

References (33)

1. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73. (Pubitemid 46454266)
2. Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011;27:651-62.
3. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213-18. (Pubitemid 40439675)
4. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 2008;42: 875-9.
5. Turner D, Mack D, Leleiko N, Walters TD, Uusoe K, Leach ST, et al. Severe pediatric ulcerative colitis: A prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91.
6. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105:1430-6.
7. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
8. de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, et al. Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14:353-8. (Pubitemid 351441324)
9. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22.
10. De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease. Aliment Pharmacol Ther 2011;33: 243-50.
11. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. (Pubitemid 47204851)
12. TernantD, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008;30:523-52.
13. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: A retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011;33: 946-64.
14. Colombel J-P, Feagan BG, Sandborn W, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 349-58.
15. Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: Antibodies and anti-TNF- levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35: 971-86.
16. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
17. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18.
18. Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 1199-206.
19. Vermeire S, Noman M, Van Assche G, Baert F, D-Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1126-31.
20. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm Bowel Dis 2009;15:1264-75.
21. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006;41:720-5. (Pubitemid 43995015)
22. Sipponen T, Kolho K-L. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010;45:872-7.
23. Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011;17: 5166-71.
24. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39.
25. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
26. Cornillie F, Shealy D, D-Haens G, Geboes K, Van Assche G, Ceuppens J, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients withCrohn's disease.Aliment Pharmacol Ther 2001;15:463-73. (Pubitemid 32242771)
27. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
28. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
29. Quail MA, Russell RK, Van Limbergen JE, Rogers P, Drummond HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756-9.
30. Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107:941-9.
31. Afif W, Loftus EVJ, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
32. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8. (Pubitemid 351501078)
33. Baert F, Noman M, Vermeire S, Van Assche G, D-Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)